P
PanTheryx
Research, development, and commercialization of products that promote intestinal health
About PanTheryx
PanTheryx is a leading health and nutrition company that specializes in the production and commercialization of products for both human and animal health and wellness markets worldwide. The company's primary strength lies in its position as the world's largest producer of bovine colostrum, a type of milk produced by cows that is rich in antibodies and beneficial for immune health, digestive health, skin health, early-life nutrition, and sports nutrition.
PanTheryx operates through three main business segments: Business-to-Business (B2B), Business-to-Consumer (B2C), and Contract Manufacturing. In the B2B segment, the company partners with reputable brands to develop and supply refined colostrum for use in dietary supplements, functional foods and beverages, early life nutrition, and animal health products. In the B2C segment, the company offers a range of consumer health and wellness products, including the TruBiotics daily probiotic brand, Life’s First Naturals colostrum supplement, and DiaResQ, a special dietary food that provides relief from diarrhea.
In the Contract Manufacturing segment, PanTheryx offers a variety of services such as encapsulating, tableting, blending, spray-drying, packaging, and turn-key manufacturing. The company works closely with top dairy farmers to ethically collect excess colostrum, ensuring that each calf benefits from the colostrum before it is collected.
In summary, PanTheryx is a vertically integrated company that leverages its position as a leading producer of bovine colostrum to offer a wide range of products and services in the health and wellness market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Boulder, United States
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 75.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Dietary Supplements, Biotechnology, Gastroenterology, Nutrition, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2020
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2023 | $52M | $209M | Undisclosed | ↗ |
| LATE VCOther financing | Jun 2019 | $50M | $200M | Perceptive Advisors | — |
Growth signals
Latest recorded traffic for PanTheryx is 3.2K monthly website visits, down 3% over the last three months. PanTheryx's team grew 3.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Pegasus Capital Advisors
Pegasus Capital
Armentum Partners
Perceptive Advisors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PanTheryx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PanTheryx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








